SANCUSO® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration; some studies show that it is effective for up to 7 days. SANCUSO has been studied in head and neck cancers, gastrointestinal cancers, breast cancer and gynecological cancers. It seems particularly suited for prevention of delayed nausea and vomiting that can be seen with drugs such as cisplatin, that distribute into fat and then come out after 72 hours, causing nausea days after administration of chemotherapy. NCCN recommends it in its Antiemesis guidelines on p. AE-2.
Sancuso [package insert]. Bedminster, NJ: ProStrakan Inc.; 2008.
McEvoy GK, ed. AHFS: Drug Information. Bethesda, MD: American Society
of Health-System Pharmacists; 2008: 2996-2998.
Read the Lay version here.